MUSCLE SPASTICITY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Muscle Spasticity Market Size and Forecast – 2026 to 2033

The Muscle Spasticity Market is anticipated to grow at a CAGR of 8.9% with USD 11.4 Bn share in 2026 and is expected to reach USD 23.7 Bn in 2033. Rising cases of neurological disorders such as multiple sclerosis, stroke, and cerebral palsy drive the muscle spasticity market. Neurological disorders affect more than 3.4 Bn people globally (around 43% of the population) and are the leading cause of illness and disability, accounting for over 443 million disability-adjusted life-years (DALYs) annually, with the global burden increasing by 18% since 1990.

Key Takeaways

• Baclofen holds the largest market share of 36.6% in 2026 owing to its rising prevalence of neurological disorders.
• Oral expected to hold largest market share of 38.9% in 2026 owing to the preference for non-invasive first-line treatment. Approximately 90% of patients prefer oral medications over injectable or intravenous treatments, owing to their convenience, ease of administration, and non-invasive nature.
• Hospital pharmacies are expected to capture a prominent 39.9% market share in 2026, owing to the high burden of severe neurological conditions requiring specialized care. Each year, approximately 15 million people worldwide experience a stroke, and many require hospital-based management for muscle spasticity and rehabilitation.
• North America is anticipated to dominate the market with a 41.4% share in 2026, supported by an aging population and rising incidence of neurological disorders. In the United States alone, nearly 800,000 people experience a stroke annually, while more than 1 million individuals live with multiple sclerosis and other neurological conditions associated with spasticity, driving sustained demand for treatment options.

Current Events and Their Impact on the Muscle Spasticity Market

Segmental Insights 

Why is Baclofen Acquiring the Largest Market Share?

Baclofen holds the largest market share of 36.6% in 2026. Rising cases of neurological disorders such as multiple sclerosis, stroke, spinal cord injuries, and cerebral palsy drive the baclofen segment in the muscle spasticity market by increasing the need to manage long-term muscle stiffness and spasms. Clinicians increasingly adopt pharmacological treatment as first-line therapy due to its effectiveness in reducing muscle tone and enhancing mobility. A growing elderly population, higher demand for rehabilitation services, and widespread availability of affordable generic formulations further support the use of Baclofen across hospital and outpatient care settings. For instance, in April 2025, Nexus Pharmaceuticals, LLC launched its Baclofen Injection Refill Kit, offering the only vial-based presentation in the market. The company states that the kit enables safer, more convenient, and timely delivery of Baclofen to healthcare systems, enhancing treatment administration efficiency.

Oral expected to hold largest market share

Oral expected to hold largest market share of 38.9% in 2026 owing to the expanding outpatient and home-based care. Growing preference for non-invasive and convenient therapies drives the oral segment in the muscle spasticity market for long-term management of muscle stiffness and spasms. Clinicians actively prescribe oral medications as first-line treatment because of their accessibility and proven clinical effectiveness. Rising cases of neurological disorders such as stroke, multiple sclerosis, and spinal cord injuries further increase demand. Expanding outpatient care services, a growing elderly population, and widespread availability of affordable generic drugs like Baclofen and Tizanidine continue to support market growth. For instance, Azurity Pharmaceuticals, Inc. received U.S. FDA approval for FLEQSUVY (Baclofen oral suspension), a concentrated formulation used to treat spasticity associated with multiple sclerosis and spinal cord injuries, including other spinal cord disorders.

Which Distribution Channel segment dominates the market? 

Hospital Pharmacies acquired the prominent market share of 39.9% in 2026. Increasing numbers of severe neurological cases requiring inpatient care and specialized treatment drive the hospital pharmacy segment in the muscle spasticity market. Healthcare providers depend on hospital pharmacies to initiate and monitor therapies for conditions such as stroke, spinal cord injury, and multiple sclerosis. The growing adoption of advanced treatment options, including intrathecal drug delivery, further boosts demand. Rising hospital admissions, expanding rehabilitation centers, and coordinated multidisciplinary care approaches also support the distribution of drugs like Baclofen through hospital pharmacy channels.

Muscle Spasticity Market Trends

• The aging global population is significantly increasing the incidence of post-stroke disability and neurodegenerative disorders. According to global health estimates, more than 15 million people suffer a stroke annually, and nearly 340% of stroke survivors develop spasticity, creating a growing need for long-term treatment and rehabilitation services.
• Rising demand for outpatient care and home-based rehabilitation services is accelerating the shift toward oral therapies and long-term medication adherence. Approximately 80–90% of patients prefer oral medications over injectable or intravenous treatments, supporting the strong adoption of oral antispasticity drugs.
• Increasing healthcare awareness and improved diagnostic rates are enabling earlier identification and treatment of spasticity-related conditions. Neurological disorders affect more than 3.4 billion people globally, increasing the potential patient pool requiring spasticity management, particularly among individuals with stroke, multiple sclerosis, cerebral palsy, and spinal cord injuries.
• Favorable reimbursement policies and expanding insurance coverage in regions such as North America and Europe are improving access to advanced therapies and rehabilitation services. In the United States, Medicare and private insurers cover a substantial portion of rehabilitation and intrathecal baclofen therapy costs, supporting broader adoption of specialized spasticity treatments and contributing to the dominance of hospital pharmacy channels, which account for nearly 39.9% of the market in 2026 due to the high volume of severe neurological cases treated in hospital settings.

Regional Insights 

North America dominates owing to high treatment awareness and diagnosis rates

North America is expected to acquire the dominant share of 41.40% in 2026. High prevalence of neurological disorders such as stroke, multiple sclerosis, spinal cord injuries, and traumatic brain injuries drives the North America muscle spasticity market by increasing the need for long-term management of muscle stiffness. In the United States, more than 795,000 people experience a stroke each year, including approximately 610,000 first-time strokes, with a stroke occurring every 40 seconds and a stroke-related death occurring approximately every 3 minutes. A growing elderly population raises the incidence of post-stroke spasticity and chronic disability. Advanced healthcare infrastructure, strong rehabilitation networks, and early diagnostic practices support greater treatment adoption. Widespread insurance coverage and clinicians’ preference for multimodal therapies further increase the use of Baclofen across the region. For instance, Allergan plc announced that the U.S. FDA has approved BOTOX (onabotulinumtoxinA) for treating lower limb spasticity in adults, helping reduce increased muscle stiffness in the ankle and toe muscles.

Asia Pacific Muscle Spasticity Market Trends

Rising cases of neurological disorders such as stroke, cerebral palsy, and multiple sclerosis drive the muscle spasticity market in Asia Pacific, while an expanding elderly population increases the risk of spasticity conditions. Neurological disorders account for approximately 10% of India's total disease burden. Healthcare providers continue to strengthen infrastructure and improve access to rehabilitation services, which boosts treatment uptake. Growing awareness of advanced therapies also supports demand. Clinicians increasingly adopt botulinum toxin injections, oral antispasmodic drugs, and physical therapy, while governments promote supportive healthcare initiatives across the region. For instance, Sakra World Hospital launched Karnataka’s first robotic-assisted neuro-rehabilitation center in Bengaluru. The facility improves patient outcomes by reducing pain and spasticity while enhancing bone density, bowel function, sleep quality, and cardiovascular fitness.

United States Muscle Spasticity Market Trends

Rising cases of neurological conditions such as multiple sclerosis, stroke, cerebral palsy, and spinal cord injuries drive demand in the United States muscle spasticity market. An aging population further increases the need for effective spasticity management solutions. Healthcare providers and patients show growing awareness of advanced treatments, including botulinum toxin injections, oral muscle relaxants, and intrathecal baclofen therapy, which boosts adoption. Strong healthcare infrastructure, high spending, and ongoing clinical research actively support innovation and expand rehabilitation and therapeutic options across care settings. For instance, Ipsen Biopharmaceuticals announced that the U.S. FDA has expanded the label of Dysport (abobotulinumtoxinA) to treat upper limb spasticity in children aged two years and above, excluding cases caused by cerebral palsy.

Japan Muscle Spasticity Market Trends

Japan’s Muscle Spasticity market is driven by its rapidly aging population and increasing cases of stroke, cerebral palsy, and neurodegenerative diseases like Parkinson’s disease. Parkinson’s disease affects approximately 150,000–200,000 people in Japan, with a prevalence of about 100–180 cases per 100,000 population, and cases are increasing steadily due to the country’s aging population. Patients and providers benefit from a strong healthcare system that supports early diagnosis and treatment. Clinicians increasingly use botulinum toxin therapies, while rehabilitation services continue to expand. Government-backed healthcare coverage improves access, and advancements in neurorehabilitation technologies encourage hospitals and specialty clinics to adopt innovative, noninvasive, and patient-focused treatment approaches across the country.

Who are the Major Companies in Muscle Spasticity Industry

Some of the major key players in Muscle Spasticity are Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.

Key News

• In September 2025, Cionic announced U.S. FDA clearance for its second-generation Neural Sleeve 2, a wearable neurotech solution designed to improve mobility. The company notes that spasticity affects a large share of stroke and multiple sclerosis patients, severely restricting movement, increasing pain, and disrupting sleep, highlighting the need for targeted wearable interventions.

Market Report Scope 

Analyst Opinion

• Muscle spasticity treatment demand is not discretionary—it is structurally driven by neurological injury and degeneration. Post-stroke spasticity alone affects an estimated 30–40% of stroke survivors, making it one of the most common long-term complications after cerebrovascular events. With stroke remaining a leading cause of adult disability globally and in aging societies like Japan, the clinical pipeline of spasticity patients is continuously replenished rather than cyclically growing.
• Pediatric neurological disorders further anchor long-term demand. Cerebral palsy affects roughly 2–3 per 1,000 live births worldwide, and a significant proportion of these patients develop persistent spasticity requiring lifelong management. In practice, this creates a stable, non-elective treatment base where rehabilitation, orthotic support, and pharmacologic intervention are not optional but essential for functional mobility.
• Neurodegenerative diseases intensify complexity and chronicity of care. Parkinson’s disease, which affects about 1% of individuals over 60 years of age, frequently presents with rigidity and spasticity-like motor impairment. In aging-heavy healthcare systems such as Japan, this translates into sustained demand pressure on neurology and rehabilitation services rather than episodic treatment cycles.
• Botulinum toxin therapy has shifted the treatment paradigm from purely rehabilitative care to targeted neuromuscular intervention. Clinical practice consistently shows high responder rates in focal spasticity management, leading neurologists to adopt repeat-injection protocols rather than short-term interventions. This has effectively standardized pharmacologic spasticity control in hospital and specialty clinic settings.

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2021-2033)
  • Baclofen
  • Botulinum Toxin
  • Diazepam
  • Tizanidine
  • Dantrolene Sodium
  • Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
  • Oral
  • Intramuscular
  • Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research interviews

• Neurologists, physiatrists, and rehabilitation medicine specialists managing spasticity cases in tertiary hospitals
• Physiotherapists and occupational therapists involved in long-term neuro-rehabilitation programs
• Hospital pharmacy heads overseeing botulinum toxin procurement and utilization patterns
• Neuro-rehabilitation clinic administrators handling stroke and cerebral palsy patient pathways

Databases

• National health registries and hospital discharge datasets
• ClinicalTrials.gov for ongoing and completed spasticity-related therapeutic studies
• PubMed and Medline indexed biomedical literature repositories
• World Health Organization (WHO) health statistics database
• Japan Ministry of Health, Labour and Welfare (MHLW) healthcare utilization data

Magazines

• Neurology-focused clinical practice magazines
• Rehabilitation medicine and physical therapy professional publications
• Neuroscience and movement disorder journals in practitioner magazine format

Journals

• The Lancet Neurology
• Journal of Neurology, Neurosurgery & Psychiatry
• Movement Disorders Journal
• Archives of Physical Medicine and Rehabilitation
• Stroke (American Heart Association journal)

Newspapers

• National and regional healthcare reporting sections in Japan
• International medical news coverage platforms reporting on neurology advancements
• Financial newspapers covering healthcare infrastructure and aging population trends

Associations

• World Federation for NeuroRehabilitation (WFNR)
• American Academy of Neurology (AAN)
• International Society of Physical and Rehabilitation Medicine (ISPRM)
• Japan Stroke Society
• Japanese Association of Rehabilitation Medicine

Public Domain sources

• World Health Organization (WHO) reports and fact sheets
• Government healthcare policy documents and white papers from Japan
• Academic open-access journals and university research publications
• Global Burden of Disease (GBD) study outputs

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years